Pharmacological modulation of HPA axis in depression New avenues for potential therapeutic benefits

Psychiatria Danubina

Volumn 25, Issue 3, 2013, Pages 299-305

  Maric, Nadja P ^a,b   Adzic, Miroslav ^c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Antidepressant; Antiglucocorticoid; Depression; Glucocorticoid; HPA

Indexed keywords

ANTIDEPRESSANT AGENT; DEXAMETHASONE; GLUCOCORTICOID ANTAGONIST; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; METYRAPONE; MIFEPRISTONE; PRASTERONE;

BRAIN FUNCTION; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; NONHUMAN; PSYCHIATRIST; SEROTONINERGIC TRANSMISSION; STRESS;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; GLUCOCORTICOIDS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM;

EID: 84885231010     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (57)

1. Amsterdam FD &Hornig-Rohan M: Adrenocortical activation and steroid suppression with ketoconazole in refractory depression. Biol Psychiatry 1993; 33:88A.
2. Anacker C, Zunszain PA, Carvalho LA, Pariante CM: The glucocorticoid receptor: pivot of depression and of antidepressant treatment? Psychoneuroendocrinology 2011; 36:415-25.
3. Arana GW, Santos AB, Laraia MT, McLeod-Bryant S, Beale MD, Rames LJ et al.: Dexamethasone for the treatment of depression: a randomized, placebo-controlled, double-blind trial. Am J Psychiatry 1995; 152:265-7.
4. Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C et al.: An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 2002; 52:386-92.
5. Belanoff JK: Methods for treating delirium using glucocorticoid receptor-specific antagonists. US20117884091 (2011).
6. Bifulco A, Brown GW, Moran P, Ball C, Campbell C: Predicting depression in women: the role of past and present vulnerability. Psychol Med 1998; 28:39-50.
7. Binder EB, Bradley RG, Liu W, Epstein MP, Deveau TC, Mercer KB et al.: Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA 2008; 299:1291-305.
8. Bottomley C, Nazareth I, Torres-González F, Svab I, Maaroos HI, Geerlings MI et al.: Comparison of risk factors for the onset and maintenance of depression. Br J Psychiatry 2010; 196:13-7.
9. Brouwer JP, Appelhof BC, van Rossum EF, Koper JW, Fliers E, Huyser J et al.: Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression. Psychoneuroendocrinology 2006; 31:1154-63.
10. Carvalho LA, Garner BA, Dew T, Fazakerley H, Pariante CM: Antidepressants, but not antipsychotics, modulate GR function in human whole blood: an insight into molecular mechanisms. Eur Neuropsychopharmacol 2010; 20:379-87.
11. Cassol-Jr OJ, Comim CM, Petronilho F, Constantino LS, Streck EL, Quevedo J et al.: Low dose dexamethasone reverses depressive-like parameters and memory impairment in rats submitted to sepsis. Neurosci Lett 2010; 473:126-30.
12. Chrousos GP: Stress and disorders of the stress system. Nat Rev Endocrinol 2009; 5:374-81.
13. Claes S: Glucocorticoid receptor polymorphisms in major depression. Ann N Y Acad Sci 2009a; 1179:216-28.
14. Claes S: Targeting the HPA axis in major depression: does it work? Invited commentary on... Antiglucocorticoids in psychiatry. Adv Psychiatr Treat 2009b; 15:250-2.
15. DeBattista C, Belanoff J, Glass S, Khan A, Horne RL, Blasey C et al.: Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol Psychiatry 2006; 60:1343-9.
16. Fitzsimons CP, van Hooijdonk LW, Schouten M, Zalachoras I, Brinks V, Zheng T, Schouten TG, Saaltink DJ, Dijkmans T, Steindler DA, Verhaagen J, Verbeek FJ, Lucassen PJ, de Kloet ER, Meijer OC, Karst H, Joels M, Oitzl MS, Vreugdenhil E: Knockdown of the glucocorticoid receptor alters functional integration of newborn neurons in the adult hippocampus and impairs fear-motivated behavior. Mol Psychiatry 2012; Aug 28 [Epub ahead of print].
17. Freeborough A &Kimpton J: Discovering new genetic and psychosocial pathways in Major Depressive Disorder: the NewMood project. Psychiatr Danub 2011; 23(Suppl 1):138-41.
18. Guidotti G, Calabrese F, Anacker C, Racagni G, Pariante CM, Riva MA: Glucocorticoid receptor and FKBP5 expression is altered following exposure to chronic stress: modulation by antidepressant treatment. Neuropsychopharmacology 2013; 38:616-27.
19. Huffman JC &Stern TA: Neuropsychiatric consequences of cardiovascular medications. Dialogues Clin Neurosci 2007; 9:29-45.
20. Jahn H, Schick M, Kiefer F, Kellner M, Yassouridis A, Wiedemann K: Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry 2004; 61:1235-44.
21. Karssen AM, Meijer OC, Berry A, Sanjuan Piñol R, de Kloet ER: Low doses of dexamethasone can produce a hypocorticosteroid state in the brain. Endocrinology 2005; 146:5587-95.
22. Lai M, McCormick JA, Chapman KE, Kelly PA, Seckl JR, Yau JL: Differential regulation of corticosteroid receptors by monoamine neurotransmitters and antidepressant drugs in primary hippocampal culture. Neuroscience 2003; 118:975-84.
23. Mardani D &Bigdelian H: The effect of dexamethasone prophylaxis on postoperative delirium after cardiac surgery: A randomized trial. J Res Med Sci 2012; 17(Spec 1): S113-S119.
24. Maric NP &Adzic M: Disfunkcionalna HPA osa i disregulacija serotonina kao autostrada depresije. In Jakovljevic M (ed): Serotonin i depresija Mitovi i činjenice, 122-136. Pro Mente, 2013.
25. Martocchia A, Stefanelli M, Falaschi GM, Toussan L, Rocchietti March M, Raja S et al.: Targets of antiglucocorticoid therapy for stress-related diseases. Recent Pat CNS Drug Discov 2013; 8:79-87.
26. McIsaac SA,Westrin A, Young AH: Antiglucocorticoids in psychiatry. Adv Psychiatr Treat 2009; 15:242-9.
27. Miller JW &Crapo L: The medical treatment of Cushing's syndrome. Endocr Rev 1993; 14:443-58.
28. Nater UM, Hoppmann C, Klumb PL: Neuroticism and conscientiousness are associated with cortisol diurnal profiles in adults-role of positive and negative affect. Psychoneuroendocrinology 2010; 35:1573-7.
29. Nihalani ND &Schwartz TL: Mifepristone, a glucocorticoid antagonist for the potential treatment of psychotic major depression. Curr Opin Investig Drugs 2007; 8:563-9.
30. Oberlander TF, Weinberg J, Papsdorf M, Grunau R, Misri S, Devlin AM: Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. Epigenetics 2008; 3:97-106.
31. Okugawa G, Omori K, Suzukawa J, Fujiseki Y, Kinoshita T, Inagaki C: Long-term treatment with antidepressants increases glucocorticoid receptor binding and gene expression in cultured rat hippocampal neurones. J Neuroendocrinol 1999; 11:887-95.
32. O'Neil A, Sanna L, Redlich C, Sanderson K, Jacka F, Williams LJ et al.: The impact of statins on psychological wellbeing: a systematic review and meta-analysis. BMC Med 2012; 10:154.
33. Otte C, Zhao S, Whooley MA: Statin use and risk of depression in patients with coronary heart disease: longitudinal data from the Heart and Soul Study. J Clin Psychiatry 2012; 73:610-5.
34. Pariante CM, Alhaj HA, Arulnathan VE, Gallagher P, Hanson A, Massey E et al.: Central glucocorticoid receptor- mediated effects of the antidepressant, citalopram, in humans: a study using EEG and cognitive testing. Psychoneuroendocrinology 2012; 37:618-28.
35. Pariante CM, Hye A, Williamson R, Makoff A, Lovestone S, Kerwin RW: The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones. Neuropsychopharmacology 2003a; 28:1553-61.
36. Pariante CM, Kim RB, Makoff A, Kerwin RW: Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. Br J Pharmacol 2003b; 139:1111-8.
37. Pariante CM, Pearce BD, Pisell TL, Owens MJ, Miller AH: Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol Pharmacol 1997; 52:571-81.
38. Peiffer A, Veilleux S, Barden N: Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain. Psychoneuroendocrinology 1991; 16:505-15.
39. Perroud N, Paoloni-Giacobino A, Prada P, Olié E, Salzmann A, Nicastro R et al.: Increased methylation of glucocorticoid receptor gene (NR3C1) in adults with a history of childhood maltreatment: a link with the severity and type of trauma. Transl Psychiatry 2011; 1:e59.
40. Rogó? Z &Go?embiowska K: Effect of metyrapone on the fluoxetine-induced change in extracellular dopamine, serotonin and their metabolites in the rat frontal cortex. Pharmacol Rep 2010; 62:1015-22.
41. Roozendaal B, McGaugh JL (2011) Memory modulation. Behav Neurosci 2011; 125:797-824.
42. Sageman, S, Brown RP: 7-keto DHEA for psychiatric use. US20128124598 (2012).
43. Sagud M, Mihaljević-Peleš A, Begić D, Vuksan-Čusa B, Kramarić M, Živković M et al: Antipsychotics as antidepressants: what is the mechanism? Psychiatr Danub 2011; 23:302-7.
44. Saponaro S, Guarnieri V, Pescarmona GP, Silvagno F: Long-term exposure to dehydroepiandrosterone affects the transcriptional activity of the glucocorticoid receptor. J Steroid Biochem Mol Biol 2007; 103:129-36.
45. Schmidt PJ, Daly RC, Bloch M, Smith MJ, Danaceau MA, St Clair LS et al: Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry 2005; 62:154-62.
46. Simic I, Adzic M, Maric N, Savic D, Djordjevic J, Mihaljevic M et al: A preliminary evaluation of leukocyte phospho-glucocorticoid receptor as a potential biomarker of depressogenic vulnerability in healthy adults. Psychiatry Res 2013a; Mar 7 [Epub ahead of print]
47. Simic I, Maric NP, Mitic M, Soldatovic I, Pavlovic Z, Mihaljevic M et al: Phosphorylation of leukocyte glucocorticoid receptor in patients with current episode of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2013b; 40:281-5.
48. Sonino N: The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 1987; 317:812-8.
49. Sovner R &Fogelman S: Ketoconazole therapy for atypical depression. J Clin Psychiatry 1996; 57:227-8.
50. Spiga F, Harrison LR, Wood SA, Atkinson HC, MacSweeney CP, Thomson F, Craighead M, Grassie M, Lightman SL: Effect of the glucocorticoid receptor antagonist Org 34850 on basal and stress-induced corticosterone secretion. J Neuroendocrinol 2007; 19:891-900.
51. Stafford L &Berk M: The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: proof of concept for the inflammatory and oxidative hypotheses of depression? J Clin Psychiatry 2011; 72:1229-35.
52. Watts AG. Glucocorticoid regulation of peptide genes in neuroendocrine CRH neurons: A complexity beyond negative feedback. Front Neuroendocrinol 2005; 26:109-130.
53. Wolkowitz OM, Reus VI, Chan T, Manfredi F, Raum W, Johnson R et al.: Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biol Psychiatry 1999a; 45:1070-4.
54. Wolkowitz OM, Reus VI, Keebler A, Nelson N, Friedland M, Brizendine L et al.: Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 1999b; 156:646-9.
55. Yau JL, Noble J, Hibberd C, Seckl JR: Short-term administration of fluoxetine and venlafaxine decreases corticosteroid receptor mRNA expression in the rat hippocampus. Neurosci Lett 2001; 306:161-64.
56. Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Ferrier IN: Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 2004; 29:1538-45.
57. Zalachoras I, Houtman R, Atucha E, Devos R, Tijssen AM, Hu P et al: Differential targeting of brain stress circuits with a selective glucocorticoid receptor modulator. Proc Natl Acad Sci U S A 2013; 110:7910-5.